Mühlebach T J, Gabay J, Nathan C F, Erny C, Dopfer G, Schroten H, Wahn V, Seger R A
Division of Immunology-Haematology, University Children's Hospital, Zürich, Switzerland.
Clin Exp Immunol. 1992 May;88(2):203-6. doi: 10.1111/j.1365-2249.1992.tb03062.x.
Recombinant interferon-gamma (rIFN-gamma) has been described to enhance phagocyte functions in vitro and in vivo in several patients with chronic granulomatous disease (CGD). To demonstrate the clinical usefulness of this treatment, 128 patients were treated in a randomized, double-blind multi-centre study with a placebo preparation or with rIFN-gamma. We analysed parameters of neutrophil oxidative and non-oxidative metabolism in 16 patients enrolled in this study. No enhanced superoxide-release was observed in patients treated with rIFN-gamma compared to placebo-treated patients. Phagocyte cytochrome b558 content also remained unchanged. Levels of four non-oxidative antimicrobial proteins (cathepsin G, azurocidine, p29b, lactoferrin) rose, fell, or remained unchanged, irrespective of treatment with rIFN-gamma or placebo.
重组干扰素-γ（rIFN-γ）已被描述为在体外和体内可增强数名慢性肉芽肿病（CGD）患者的吞噬细胞功能。为证明这种治疗方法的临床实用性，128名患者参与了一项随机、双盲多中心研究，分别接受安慰剂制剂或rIFN-γ治疗。我们分析了参与本研究的16名患者中性粒细胞氧化和非氧化代谢的参数。与接受安慰剂治疗的患者相比，接受rIFN-γ治疗的患者未观察到超氧化物释放增强。吞噬细胞细胞色素b558含量也保持不变。四种非氧化抗菌蛋白（组织蛋白酶G、天青杀素、p29b、乳铁蛋白）的水平上升、下降或保持不变，与是否接受rIFN-γ或安慰剂治疗无关。
